Speaker Profile
Biography
Dr. Basu has over15 years of experience in clinical informatics and bioinformatics, leading initiatives that improve clinical outcomes and support biomarker discovery. Her group develops computational models using machine learning to derive adverse event signatures linked to genotype and phenotype in early=stage high-risk breast cancer. She currently co-leads the electronic Patient-Reported Outcomes Initiative (ePRO) within I-SPY, a neoadjuvant breast cancer clinical trial and is working with other teams to seamlessly integrate PROs into the clinical workflow. She is also a recipient of the White House Presidential Innovation Fellowship (PIF) (2016-2017). Dr. Basu received her Bachelors degree in Electrical Engineering from Cornell University and her PhD from Rockefeller University.
Talk
Artificial intelligence (AI) approaches are increasingly used to track patient health real time. These tools also may provide novel biological insights and improve risk prediction of unexpected toxicities upon combination treatment. We develop these tools to better understand clinical outcomes using trial and routine clinical care data in the context of high risk breast cancer.